Open-House-Biologika-Rabattverträge 2025-21 - Teriparatid
Original notice title
Germany – Pharmaceutical products – Open-House-Biologika-Rabattverträge 2025-21 - Teriparatid
Opportunity Score
Why this score?
Opportunity
50 / 100
Complexity
30 / 100
Risk factors
No estimated value or framework maximum means potential volume is unknown.
Electronic submission is not allowed via the portal; requires email with QES or postal submission with scanned copy.
Deep Portfolio Analysis
Uses:
- Description
- Industries & Services
- Capabilities
- Market & Experience
- Certifications
Tender facts
- Contracting authority
- Techniker Krankenkasse
- Country
- Germany
- CPV
- 33600000 - Pharmaceutical products
- Deadline
- Aug 30, 2027
Overview
Moderate opportunityKey Facts
- Supplies contract
- 1 lot
- Duration until Aug 2027
- Pharmaceutical discount agreement for Teriparatid
- Supply of the active substance to German statutory health insurance funds
Show full summary
Open-House procedure by Techniker Krankenkasse and other German health insurers to conclude discount agreements (Rabattverträge) for the active substance Teriparatid. The procedure allows any eligible pharmaceutical entrepreneur to join at any time during the contract period (01.09.2025 to 31.08.2027). No exclusive rights are granted. The notice explicitly states this is not a public procurement subject to EU procurement law; legal disputes fall under social courts. No estimated value, award criteria, or detailed submission documents were provided in the structured data or XML notice.
Risks
No estimated value or framework maximum means potential volume is unknown.
Electronic submission is not allowed via the portal; requires email with QES or postal submission with scanned copy.
Analysis may be incomplete
Only part of the procurement documentation was analyzed. Additional eligibility requirements, certificates, or submission documents may exist in the remaining tender documentation.
Key Requirements
Technical
- Must be a pharmaceutical entrepreneur (pharmazeutischer Unternehmer) per § 4 Abs. 18 AMG
- Must have a valid marketing authorization for the medicinal product per § 21 AMG
- Must have registered seat in Germany, EU, or EEA
Requirements may be incomplete.
Award Criteria
Lot 1
Buyer
Location
Hamburg, DEU
Website
Identifier
992-80116-93
Activity
Health
Lots (1)
LOT-0001
Open-House-Biologika-Rabattverträge 2025-21 - Teriparatid
Conclusion of pharmaceutical discount agreements for Teriparatid under § 130a Abs. 8 SGB V via an open-house procedure. No negotiation, uniform terms. Contract duration max 24 months from 01.09.2025 to 31.08.2027.
Location
Duration
Category
Award Criteria
Deadline
Award details
Ziel ist der Abschluss von Arzneimittelrabattverträgen nach § 130a Abs. 8 SGB V zu dem Wirkstoff Teriparatid im Rahmen eines Open-House-Verfahrens.
Value note
Show original TED data
Original TED description
Ziel ist der Abschluss von Arzneimittelrabattverträgen nach § 130a Abs. 8 SGB V zu dem Wirkstoff Teriparatid im Rahmen eines Open-House-Verfahrens.
Procurement Details
- Publication date
- 13 Jul 2025
- Languages
- German
Reference metadata
- Legal basis
- 32014L0024
Reference IDs
- Tender ID
- 457552-2025
Documents (1)
Similar tenders
Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)
Germany – Pharmaceutical products – Abschluss nicht-exklusiver Rabattvereinbarungen nach § 130a Abs. 8 SGB V zu den genannten Wirkstoffen mit Abschlussmöglichkeit im Rahmen des sogenannten Open-House-Verfahrens.
Germany – Pharmaceutical products – Open House Biologika Rabattverträge 2026 - 27 - Follitropin delta
Opportunity Score
Why this score?
Opportunity
50 / 100
Complexity
30 / 100
Risk factors
No estimated value or framework maximum means potential volume is unknown.
Electronic submission is not allowed via the portal; requires email with QES or postal submission with scanned copy.
Deep Portfolio Analysis
Uses:
- Description
- Industries & Services
- Capabilities
- Market & Experience
- Certifications